---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-22-004819"
form_type: "8-K"
ticker: "XBIO"
cik: "0001534525"
company_name: "Xenetic Biosciences, Inc."
filed_at: "2022-07-07T23:59:59+00:00"
generated_at: "2026-06-24T19:32:17.294135+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Xenetic enters manufacturing agreement with Catalent for DNase clinical supply up to $5M

## Summary
- Estimated project cost up to ~$5M for cGMP manufacturing of Human DNase I over ~17 months.
- Catalent to provide manufacturing services for clinical supply to support planned Phase 1 study.
- DNase platform targets NETs to enhance efficacy of immunotherapies and chemotherapies in solid tumors.
- Initial indication focus includes pancreatic carcinoma, a multi-billion-dollar market.
- CEO Jeffrey Eisenberg says this is an important step towards first-in-human studies.

## SEC filing metadata
- accession: 0001683168-22-004819
- form_type: 8-K
- ticker: XBIO
- cik: 0001534525
- company_name: Xenetic Biosciences, Inc.
- filed_at: 2022-07-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534525/000168316822004819/0001683168-22-004819-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534525/000168316822004819/xenetic_8k-070622.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-22-004819
- JSON: https://secwatch.observer/filing/0001683168-22-004819.json
- Plain text: https://secwatch.observer/filing/0001683168-22-004819.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.